Tillman Hartley LLC Cuts Stock Position in Eli Lilly and Company (NYSE:LLY)

Tillman Hartley LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 2.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 602 shares of the company’s stock after selling 16 shares during the quarter. Tillman Hartley LLC’s holdings in Eli Lilly and Company were worth $465,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Bowen Hanes & Co. Inc. boosted its stake in Eli Lilly and Company by 2.6% during the 4th quarter. Bowen Hanes & Co. Inc. now owns 128,550 shares of the company’s stock worth $99,241,000 after purchasing an additional 3,236 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in Eli Lilly and Company by 1.4% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 336,599 shares of the company’s stock worth $260,474,000 after purchasing an additional 4,722 shares during the last quarter. Tredje AP fonden boosted its stake in Eli Lilly and Company by 15.9% during the 4th quarter. Tredje AP fonden now owns 240,123 shares of the company’s stock worth $185,375,000 after purchasing an additional 33,020 shares during the last quarter. Avantax Advisory Services Inc. boosted its stake in Eli Lilly and Company by 10.7% during the 4th quarter. Avantax Advisory Services Inc. now owns 51,279 shares of the company’s stock worth $39,587,000 after purchasing an additional 4,937 shares during the last quarter. Finally, Essential Planning LLC. boosted its stake in Eli Lilly and Company by 6,406.9% during the 4th quarter. Essential Planning LLC. now owns 716,081 shares of the company’s stock worth $593,544,000 after purchasing an additional 705,076 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.2 %

Shares of LLY opened at $822.26 on Thursday. The firm has a market cap of $779.64 billion, a P/E ratio of 70.22, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company’s 50-day moving average price is $829.78 and its 200 day moving average price is $845.29. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a share buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup lowered their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Finally, Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.